FOXO TECHNOLOGIES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.28 USD | -2.10% |
|
+3.47% | -12.42% |
| Apr. 24 | Sector Update: Tech Stocks Higher Premarket Wednesday | MT |
| Apr. 24 | FOXO Technologies Gets Non-Compliance Notice From NYSE American | MT |
Financials (USD)
| Sales 2021 | 120K | Sales 2022 | 511K | Capitalization | 11.82M |
|---|---|---|---|---|---|
| Net income 2021 | -38M | Net income 2022 | -95M | EV / Sales 2021 | 2,341 x |
| Net Debt 2021 | 25.35M | Net cash position 2022 | 1.88M | EV / Sales 2022 | 19.5 x |
| P/E ratio 2021 |
-0.52
x | P/E ratio 2022 |
-0.05
x | Employees | 4 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 64.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on FOXO Technologies Inc.
More press releases
| 1 day | -2.10% | ||
| 1 week | +3.47% | ||
| Current month | -31.20% | ||
| 1 month | -20.00% | ||
| 3 months | -5.66% | ||
| 6 months | -71.43% | ||
| Current year | -12.42% |
1 week
0.27
0.31
1 month
0.260.45
Current year
0.260.45
1 year
0.255.28
3 years
0.25110.00
5 years
0.25110.00
10 years
0.25110.00
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.28 | -2.10% | 147,292 |
| 24-04-23 | 0.286 | -2.36% | 237,432 |
| 24-04-22 | 0.2929 | +9.70% | 518,889 |
| 24-04-19 | 0.267 | -3.68% | 196,295 |
| 24-04-18 | 0.2772 | +2.44% | 123,392 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotes
FOXO Technologies Inc. is a biotechnology company. The Company is focused on commercializing longevity science through products and services that serve the life insurance industry. Its epigenetic technology applies artificial intelligence (AI) to deoxyribonucleic acid (DNA) methylation to identify molecular biomarkers of human health and aging. The Company operates through two segments: FOXO Labs and FOXO Life. FOXO Labs is commercializing epigenetic biomarker technology to be used for mortality underwriting and risk classification in the global life insurance industry. Its biomarker technology enables the adoption of new saliva-based health and wellness biomarker solutions for underwriting and risk assessment. FOXO Life is redefining the relationship between consumers and insurers by combining life insurance with healthy longevity. FOXO Life seeks to transform the value proposition of the life insurance carrier from a provider of mortality risk protection products.
Sector
IT Services & Consulting
Calendar
2024-11-10
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.42% | 2.5M | |
| -10.65% | 197B | |
| +1.83% | 166B | |
| +12.56% | 169B | |
| +5.85% | 101B | |
| +5.79% | 76.87B | |
| +16.57% | 71.98B | |
| -6.47% | 71.09B | |
| -22.12% | 51.76B | |
| +3.05% | 48.08B |
- Stock Market
- Equities
- FOXO Stock
